Licensing status

Publication and contact information

Infectious disease

Herpes simplex virus (HSV)

glycoprotein B

Mouse studies suggest the mAb hu2c could prevent or treat drug-resistant HSV infections. In an immunodeficient mouse model for HSV-1 infection, 15 mg/kg of systemically delivered hu2c, a humanized mAb targeting HSV glycoprotein B, protected mice from viral challenge and led to clearance of virus in pre-established infection. In immunodeficient mice infected with a multidrug-resistant strain of HSV-1, hu2c completely cleared the virus in seven of eight mice, whereas acyclovir had only minor effects on viral load. Ongoing work includes tests of hu2c in HSV-2-infected animals and clinical development of the antibody.

SciBX 6(15); doi:10.1038/scibx.2013.365
Published online April 18, 2013

Patent application filed; available for licensing

Krawczyk, A. et al. Proc. Natl. Acad. Sci. USA; published online
April 8, 2013;
Contact: Jürgen Krauss, Heidelberg University Medical Center,
Heidelberg, Germany